Thus, our use of HeLa tumor bearing models with IFN- γ treatment enabled us to confirm that [18F]IDO49 accumulation in the IFN-γ treatment tumor mouse was due to in vivo targeting of activated IDO1 expression rather than nonspecific retention. This evidence concerns the gene IFNG and neoplasm.